With many of the usual targets on display Fate, Celyad, Allovir and others look to maintain momentum.
Notable progress with antibody-drug conjugates from Seattle Genetics and Immunomedics drove the biggest Esmo share price moves.
Though late-breakers rightfully seize much of the limelight at the Esmo congress, investors should look further afield too.
Adaptimmune and Allogene led numerous cell therapy companies higher over the Asco period, while Cytomx and Arvinas suffered the biggest losses.
An early look at data from the huge cancer conference boosts Allogene and Immunogen, while Arvinas and Cytomx suffer.
The Chinese group sees responses in all five subjects treated with its allogeneic anti-CD7 Car-T therapy.
Celgene’s registrational Transcend NHL-001 study will be a big story at Ash, but the early focus falls on what has not been presented.
The biotech calendar’s next key conference gets under way in a month, and a presentation by Nextcure will be a focus for some investors.